DDInter1175 DDInter1376
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Methotrimeprazine {u} (Compound) resembles {v} (Compound) Moricizine
Methotrimeprazine {u} (Compound) resembles {v} (Compound) Aceprometazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Methotrimeprazine {u} (Compound) binds {v} (Gene) ADRA1D
Methotrimeprazine {u} (Compound) upregulates {v} (Gene) CNPY3
Methotrimeprazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Methotrimeprazine {u} (Compound) causes {v} (Side Effect) Urinary retention
Methotrimeprazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Methotrimeprazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Methotrimeprazine (Compound) resembles Moricizine (Compound)
Methotrimeprazine (Compound) resembles Aceprometazine (Compound)
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methotrimeprazine (Compound) binds ADRA1D (Gene)
Methotrimeprazine (Compound) upregulates CNPY3 (Gene)
Methotrimeprazine (Compound) downregulates TXNDC9 (Gene)
Methotrimeprazine (Compound) causes Urinary retention (Side Effect)
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate